ABT-869

Vegf, Etc – Boring & Healthy…Tons of Ph2s in HCC but is it better then Sorafenib?

no news is good news?

previously

ABT-869

Phase 2 on the doorstep, Genentech and Abbott just announced a collaboration to include development of the compound w/ backups. No terms disclosed…

Vegf, Flt3, Tie2, c-FMS, Pdgf, c-kit yadda yadda

j med chem, blood, molec cancer ther., WO/2004/113304

A-[CEP-701]

So, what’s Abbott doing making solid forms of Lestaurtinib?

WO/2007/070444, US20070135628, US20070135401

Oh, and CC pointed out that CEP-701 / lestaurtinib is claimed to be in Ph3 trials for AML, so add that one to the list, I guess. I can’t find the trial in the US or EU databases, so may be in Asia?

PDB Update

Some kind of coincidence that this week’s update are all indazoles? Hmm…

2UZT Abbott; AKT;
2UZU A-443654
2UZV
2UZW

The real action with these is what’s going on with the indole though.

PDB Update

Abbott’s got an anilinopyrimidine bound to Jnk1 with 2No3; BMCL. Their other JNK1 structure is 2g01

PDB Update

2GHG Abbott – Chk1 with A431994 (Akt inhibitor) BMCL ‘06, 3424

I haven’t read the article yet, but to my eye the PDB suggests a ligand conformation responsible for some off target activity. Abbott’s indole-aminoethoxides in last weeks update (2OH0, 2OJF) seem to be the more typical (potent?) conformation.

Abbott: not done with P38 either

WO/2007/028051 is another p38 application suggesting that Abbott isn’t throwing in the towel just yet

Who’s in CA?

No, not Canada, A? SF, CA – Here, have a sequal to the Prague entry: This is what you’re missing at YawnFest ‘07, err I mean: the MMTC:

Wyeth talks Src/Abl: SKI-606 (American Cyanamid: WO/2000/018740)

Roche talks P38: R1487

And a former Abbot guy is talkinig LCK: A-770041

all great compounds and yadda yadda, just having a hard time seeing anything new here.

US20060270663

Hi Abbott, VEGF / TIE2 inhibitor, eh? Check 1ywn for similar.

nuff said.